News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Zealand Pharma  (ZEAL.CO) Informs of New Scientific Presentations on Lyxumil® (lixisenatide) and on Proprietary GLP-1-Gastrin Dual Agonist at the EASD 49th Annual Meeting



9/20/2013 9:58:29 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) informs that new sub-analyses of data relating to Lyxumia® (lixisenatide) and new preclinical data relating to ZP3022, a compound from Zealand’s proprietary GLP-1-gastrin dual acting receptor agonist program for the potential treatment of diabetes, will be presented at the European Association for the Study of Diabetes (EASD) 49th Annual Meeting on 23 – 27 September 2013 in Barcelona, Spain. Lyxumia® (lixisenatide), discovered by Zealand and licensed globally to Sanofi, is the first once-daily prandial GLP-1 receptor agonist marketed for the treatment of adults with type 2 diabetes.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES